P1.12-01 a Single-Arm Multi-Center Phase II Study of Apatinib in Patients With ES-SCLC After Second/Third-Line Chemotherapy

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.836
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Apatinib Monotherapy as a Second-Line Treatment for Patients With Advanced Biliary Tract Cancer: A Retrospective Single-Center Observational Study

2019English

A Multi-Center Phase II Study and Biomarker Analysis of Combined Cetuximab and Modified FOLFIRI as Second-Line Treatment in Patients With Metastatic Gastric Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

P109 Combined Chemotherapy Versus Topotecan Monotherapy as Second-Line Treatment for Patients With Sensitive Relapsed SCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Phase II Study of Second-Line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma

Anticancer Research
MedicineCancer ResearchOncology
2020English

Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2018English

P1.12-03 a Prospective Study of Apatinib in Advanced Small Cell Lung Cancer Patients Failed From Two or More Lines of Chemotherapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Mitomycin C and Vinorelbine for Second-Line Chemotherapy in NSCLC – A Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2007English

Cetuximab and Irinotecan as Third-Line Therapy in Advanced Colorectal Cancer Patients: A Single Centre Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2006English

OA08.01 Long-Term Efficacy and Safety of Nivolumab in Second- Or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy